Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 103,744

Document Document Title
WO/2021/089764A1
The present invention relates to diagnostic methods to assess the presence of quorum sensing molecules (QSM), preferably peptides (QSPs), that influence muscle wasting in humans. The present invention furthermore relates to the use of th...  
WO/2021/092354A1
Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with ...  
WO/2021/091902A1
In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the ad...  
WO/2021/088317A1
Provided are an miRNA marker for the diagnosis and/or treatment of Alzheimer's disease. The miRNA marker is an miRNA-23 cluster. Also provided are the use of the microRNA of the miRNA-23 cluster in the diagnosis and/or treatment of Alzhe...  
WO/2021/092589A1
The disclosed subject matter provides for genetically modified cells, e.g, fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g, therapeutic peptides, therapeutic proteins or small therapeutic ...  
WO/2021/089715A1
Use of colchicine to inhibit, delay, or reduce the occurrence of lung cancer in a subject with cancer, comprising administering to the subject an effective amount of colchicine is provided.  
WO/2021/092543A1
Provided are methods for treating a disease, disorder, or condition associated with an acid ceramidase (AC) biological activity. The methods include administering to a subject in need thereof a composition including an AC inhibitor and a...  
WO/2021/092499A1
Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, ...  
WO/2021/089791A1
Resistance to kinase inhibitors exemplifies the greatest hindrance to effective treatment of cancer patients. Recent studies have suggested that the onset of said resistance might not only be explained by a drug selection of pre-existing...  
WO/2021/091209A1
The present invention relates to a composition for the prevention, amelioration, or treatment of infectious diseases caused by nontuberculous mycobacteria. A compound represented by chemical formula 1 of the composition according to the ...  
WO/2021/088938A1
The present invention relates to a tetrahydropyridopyrimidine-based inhibitor, a preparation method therefor and use thereof. Specifically, the compound has a structure represented by formula (I), each of the groups and substituents are ...  
WO/2021/091950A1
The disclosure provides polynucleotides containing SLC6A14 promoters, as well as vectors containing the same, that can be used to promote expression of a transgene in vestibular supporting cells. The polynucleotides described herein may ...  
WO/2021/089300A1
The present invention relates to compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3- isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and/or TT002), or a pharmaceutical composition comprising said TT00, TT001 and/or TT0...  
WO/2021/023069A8
Provided is an application of thiamine pyrophosphokinase TPK as a target in the treatment or prevention of Alzheimer's disease; using TPK as a target, brain TPK protein kinase activity or/and expression levels are promoted, preventing AD...  
WO/2021/089649A1
Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyrid...  
WO/2021/092059A1
Disclosed are methods and compositions for treating cell proliferative diseases and disorders including cancers comprising tumor-associated myeloid cells (TAMCs) such as glioblastoma. The disclosed methods and composition may utilize or ...  
WO/2021/092190A1
Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequina...  
WO/2021/092562A1
Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally i...  
WO/2021/090172A1
Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface and/or that enhance the activity of GLP-1, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatmen...  
WO/2021/085696A1
The present invention relates to small lipid nanoparticles, a small lipid nanoparticle (SLNP)-based nanovaccine platform including same, and a combination treatment regimen with an immune checkpoint inhibitor. Lipid nanoparticles accordi...  
WO/2021/083959A1
The present invention relates to a compound ABT-263 or a derivative thereof for use in the treatment of uveal melanoma and/or uveal melanoma resistant. Inventors provide evidence that ABT-263 displays clear antiproliferative and proapopt...  
WO/2021/084791A1
The purpose of the invention is to identify a new receptor participating in the differentiation of helper T cells and to develop a drug targeted thereto. It has been discovered that an adenosine A2A receptor participates in control of th...  
WO/2021/087458A2
The present disclosure provides methods of treating cancer in a patient determined to have a p53 mutation by administering an inhibitor of nonsense mediated decay. The patient may be further administered an inhibitor of mRNA splicing and...  
WO/2021/084062A1
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survi...  
WO/2021/087439A1
Embodiments of the disclosure include methods and compositions useful for treating cancer in an immunogenic manner so as to elicit local tumor regression, while priming systemic immunity. In one embodiment, there is expansion of tumor-sp...  
WO/2021/084541A1
Disclosed are topical compositions and methods of treatment of hair loss by topical administration to a subject in need thereof of a composition comprising a therapeutically effective amount of at least one EGFR inhibitor and optionally ...  
WO/2021/083964A1
The present invention relates to the field of DNA virus infection, in particular to therapy and diagnosis of a DNA virus infection in a subject. Specifically, the present invention relates to the use of arsenic trioxide (As2O3) for treat...  
WO/2021/085872A1
The present invention relates to a composition, comprising a Salvia plebeia R. Br. extract as an active ingredient, for inhibiting tumor growth. A Salvia plebeia R. Br. extract was found to bind to PD-L1 present on cancer cell surfaces t...  
WO/2021/085633A1
[Problem] To improve permeability of skin external agents such as cosmetics into the skin. [Solution] When applying, to the skin, a skin external agent that contains a specific component to be applied to the skin of a right hand (1R), fo...  
WO/2021/087177A1
Embodiments of the disclosure encompass methods and compositions related to overcoming or preventing cancer resistance to anti-apoptotic proteins, for example BH3 mimetics. The disclosure provides methods for modulating p73 to reduce can...  
WO/2021/084765A1
The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.  
WO/2021/087072A1
The present disclosure relates to compositions and uses thereof for preventing and treating respiratory syncytial virus (RSV) infection. In some aspects, disclosed herein is a method for preventing or treating respiratory syncytial virus...  
WO/2021/082882A1
Disclosed is a method for anchoring and modifying a nano-drug on the surface of a living cell. The method comprises: introducing an active reaction group to the surface of a living cell by means of a hydrophobic tail chain of a cell memb...  
WO/2021/083593A1
The present invention relates to a kit, comprising at least one cold spray and at least one dosage form for transdermally administering at least one pharmaceutically active ingredient, to said kit for use in the treatment of a patient, t...  
WO/2021/059270A3
Methods of treating a disease characterized by mRNA instability or nonsense-mediated decay of an mRNA of a disease-associated gene in a subject by administering a pharmaceutical composition comprising at least one agent that decreases FT...  
WO/2021/085295A1
The present invention addresses the problem of clarifying the immune response mechanism of IL-17-producing cells, said immune response mechanism inducing pathological conditions such as psoriasis, to thereby provide an immune response su...  
WO/2021/086909A1
The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N- benzyl-8-({6-[3-(4-ethylpiperazin-l-yl)aze...  
WO/2021/086610A1
This invention relates to the use of plant extracts, compositions thereof, and compounds isolated from plant extracts or obtained from synthetic means thereof, for the treatment of diseases, disorders or symptoms thereof (e.g., prolifera...  
WO/2021/085497A1
An example of the combination drug of the present invention, which is to be used for treating caner in a target, comprises (a1) an immune responsive cell expressing a cell-surface molecule specifically recognizing a cancer antigen, inter...  
WO/2021/086912A1
Disclosed is a method for treating a cancer in a mammal in need thereof, comprising administering to the mammal a combination of effective amount of an autophagy inhibitor and a p38 mitogen-activated protein kinase (p38 MAPK) inhibitor, ...  
WO/2021/086567A1
Infections caused by multidrug-resistant (MDR) bacteria, particularly Gram-negative bacteria, are an escalating global health threat. Often clinicians are forced to administer the last resort antibiotic colistin, however colistin resista...  
WO/2021/086967A1
The present invention relates to a method of treating subjects with diabetic nephropathy by administering certain dosages of Compound I, a stimulator of soluble guanylate cyclase (sGC), either alone or in combination therapy.  
WO/2021/078246A1
In order to overcome the problems of poor therapeutic effects and large side effects of existing treatment methods and therapeutic medicines for sepsis, provided is a pharmaceutical composition for preventing or treating sepsis, comprisi...  
WO/2021/081108A1
The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), (I), or...  
WO/2021/079887A1
The present invention provides a preventative or therapeutic agent for tauopathy, that contains an α2δ inhibitor for voltage-gated calcium channels.  
WO/2021/081481A1
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for preventing tumor recurrence and metastases. In one embodiment, a method for inhibiting lung cance...  
WO/2021/077566A1
An application of divalent manganese in preparing an immunity enhancing drug or anti-tumor drug, specifically relating to divalent manganese being used as an activator of dendritic cells, macrophages or CD8 positive T cells, and a use th...  
WO/2020/181295A8
The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective...  
WO/2021/080312A1
The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of chemical formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating, or treating cognitive disor...  
WO/2021/079988A1
This agent for promoting odontoblast propagation and differentiation contains a calcium salt of 4-(meth)acryloyloxyethyltrimellitic acid.  

Matches 1 - 50 out of 103,744